OTCMKTS:PTQQF - Protech Home Medical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.87
  • Forecasted Upside:
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)

This chart shows the closing price for PTQQF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Protech Home Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTQQF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTQQF

Analyst Price Target is $2.87
▲ +∞ Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Protech Home Medical in the last 3 months. The average price target is $2.87, with a high forecast of $3.10 and a low forecast of $2.50. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for PTQQF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Protech Home Medical.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/3/2021Stifel NicolausBoost Price TargetBuy$2.60 ➝ $3.10
2/2/2021Canaccord GenuityBoost Price TargetBuy$2.00 ➝ $2.50
1/25/2021Raymond JamesBoost Price TargetOutperform$2.00 ➝ $3.00
7/6/2020Canaccord GenuityInitiated CoverageBuy
5/21/2020Dougherty & CoInitiated CoverageBuy
(Data available from 11/27/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

Protech Home Medical

Protech Home Medical Corp. provides in-home monitoring equipment, supplies, and services for patients in the United States. It offers daily and ambulatory aides; power mobility equipment; BiPAP and CPAP machines, oxygen concentrators, and ventilators; oxygen therapy; sleep apnea and PAP treatment equipment; disease management services; and home ventilator equipment, as well as rents respiratory equipment. The company was formerly known as Patient Home Monitoring Corp. and changed its name to Protech Home Medical Corp. in April 2018. Protech Home Medical Corp. was incorporated in 1993 and is headquartered in Wilder, Kentucky.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $2.64
Low: $1.64
High: $7.43

52 Week Range

Now: N/A

Volume

298,100 shs

Average Volume

188,270 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Protech Home Medical?

The following Wall Street research analysts have issued reports on Protech Home Medical in the last twelve months: Canaccord Genuity, Raymond James, and Stifel Nicolaus.
View the latest analyst ratings for PTQQF.

What is the current price target for Protech Home Medical?

3 Wall Street analysts have set twelve-month price targets for Protech Home Medical in the last year. Their average twelve-month price target is $2.87. Stifel Nicolaus has the highest price target set, predicting PTQQF will reach $3.10 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $2.50 for Protech Home Medical in the next year.
View the latest price targets for PTQQF.

What is the current consensus analyst rating for Protech Home Medical?

Protech Home Medical currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTQQF will outperform the market and that investors should add to their positions of Protech Home Medical.
View the latest ratings for PTQQF.

What other companies compete with Protech Home Medical?

How do I contact Protech Home Medical's investor relations team?

The company's listed phone number is 859 300 6455. The official website for Protech Home Medical is www.protechhomemedical.com.